| Name | Title | Contact Details |
|---|---|---|
Salvatore Privitera |
Chief Technology Officer | Profile |
CeQur is dedicated to helping people with type 2 diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life. The company`s lead product, PaQ, is a wearable insulin delivery device that delivers both basal and bolus insulin for 3 days at a time. Its simple, discreet design enables people to easily experience the benefits of intensive insulin therapy, while remaining free from the burdens of daily insulin injections. CeQur SA was established in January 2008 as a spinout from Danfoss A/S, a global Danish industrial products group that developed the initial concept of the CeQur technology. CeQur recently completed a clinical study evaluating PaQ among people with type 2 diabetes with positive results. The company has advanced the technology to a commercial product obtaining a CE mark for PaQ in 2012. CeQur is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.
Rees Scientific Corp. is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Hudson Optical is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Immunicon Corporation is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.